EP1859797 - CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT [Right-click to bookmark this link] | |||
Former [2007/48] | NOVEL CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT | ||
[2014/21] | Status | The application is deemed to be withdrawn Status updated on 13.02.2015 Database last updated on 31.08.2024 | Most recent event Tooltip | 13.02.2015 | Application deemed to be withdrawn | published on 18.03.2015 [2015/12] | Applicant(s) | For all designated states Eisai R&D Management Co., Ltd. 6-10, Koishikawa 4-chome, Bunkyo-ku Tokyo 112-8088 / JP | [2007/48] | Inventor(s) | 01 /
OWA, Takashi c/o Tsukuba Res. Labs, Eisai Co., Ltd. 1-3, Tokodai 5-chome Tsukuba-shi Ibaraki 3002635 / JP | 02 /
OZAWA, Yoichi Tsukuba Res. Labs, Eisai Co., Ltd. 1-3, Tokodai 5-chome Tsukuba-shi Ibaraki 3002635 / JP | 03 /
SEMBA, Taro Tsukuba Res. Labs, Eisai Co., Ltd 1-3, Tokodai 5-chome Tsukuba-shi, Ibaraki 3002635 / JP | 04 /
HATA, Naoko Tsukuba Res. Labs, Eisa Co., Ltd 1-3, Tokodai 5-chome Tsukuba-shi, Ibaraki 3002635 / JP | [2007/48] | Representative(s) | Woods, Geoffrey Corlett, et al J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | [N/P] |
Former [2007/48] | Woods, Geoffrey Corlett, et al J.A. KEMP & CO. Gray's Inn 14 South Square London WC1R 5JJ / GB | Application number, filing date | 06715262.9 | 28.02.2006 | [2007/48] | WO2006JP304219 | Priority number, date | JP20050055132 | 28.02.2005 Original published format: JP 2005055132 | [2007/48] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2006090931 | Date: | 31.08.2006 | Language: | JA | [2006/35] | Type: | A1 Application with search report | No.: | EP1859797 | Date: | 28.11.2007 | Language: | EN | [2007/48] | Search report(s) | International search report - published on: | JP | 31.08.2006 | (Supplementary) European search report - dispatched on: | EP | 15.03.2011 | Classification | IPC: | A61K31/18, A61K31/343, A61K31/381, A61K31/404, A61K31/4741, A61K31/498, A61K31/7068, A61K33/24, A61K45/06, A61P9/00, A61P35/00 | [2011/15] | CPC: |
A61K31/498 (EP,US);
A61K31/18 (EP,US);
A61K31/343 (EP,US);
A61K31/381 (EP,US);
A61K31/404 (EP,US);
A61K31/4741 (EP,US);
A61K31/7068 (EP,US);
A61K33/243 (EP,US);
A61K45/06 (EP,US);
| C-Set: |
A61K31/18, A61K2300/00 (US,EP);
A61K31/343, A61K2300/00 (US,EP);
A61K31/381, A61K2300/00 (US,EP);
A61K31/404, A61K2300/00 (US,EP);
A61K31/4741, A61K2300/00 (EP,US);
A61K31/498, A61K2300/00 (EP,US); |
Former IPC [2007/48] | A61K31/404, A61K31/18, A61K31/343, A61K31/381, A61K31/4741, A61K31/498, A61K31/7068, A61K33/24, A61K45/00, A61P9/00, A61P35/00 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/48] | Extension states | AL | 25.09.2007 | BA | 25.09.2007 | HR | 25.09.2007 | MK | 25.09.2007 | YU | 25.09.2007 | Title | German: | GLEICHZEITIGE VERWENDUNG EINER SULFONAMID-VERBINDUNG UND EINES MITTELS GEGEN KREBS | [2014/21] | English: | CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT | [2014/21] | French: | UTILISATION CONCOMITANTE D'UN COMPOSE DE SULFONAMIDE AVEC UN AGENT ANTI-CANCER | [2014/21] |
Former [2007/48] | NEUE GLEICHZEITIGE VERWENDUNG EINER SULFONAMID-VERBINDUNG UND EINES MITTELS GEGEN KREBS | ||
Former [2007/48] | NOVEL CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT | ||
Former [2007/48] | NOUVELLE UTILISATION CONCOMITANTE D'UN COMPOSE DE SULFONAMIDE AVEC UN AGENT ANTI-CANCER | Entry into regional phase | 25.09.2007 | Translation filed | 25.09.2007 | National basic fee paid | 25.09.2007 | Search fee paid | 25.09.2007 | Designation fee(s) paid | 25.09.2007 | Examination fee paid | Examination procedure | 25.09.2007 | Examination requested [2007/48] | 04.10.2011 | Amendment by applicant (claims and/or description) | 10.05.2012 | Despatch of a communication from the examining division (Time limit: M04) | 03.09.2012 | Reply to a communication from the examining division | 28.04.2014 | Communication of intention to grant the patent | 09.09.2014 | Application deemed to be withdrawn, date of legal effect [2015/12] | 15.10.2014 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2015/12] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 10.05.2012 | Fees paid | Renewal fee | 13.02.2008 | Renewal fee patent year 03 | 13.02.2009 | Renewal fee patent year 04 | 16.02.2010 | Renewal fee patent year 05 | 15.02.2011 | Renewal fee patent year 06 | 22.02.2012 | Renewal fee patent year 07 | 21.02.2013 | Renewal fee patent year 08 | 20.02.2014 | Renewal fee patent year 09 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [YA]EP1331005 (EISAI CO LTD [JP]) [Y] 1,8,9,11,14-16,20,21,25,27,28 * paragraphs [0001] - [0002] - [0 37] * * claims 1, 3, 5-19 * [A] 2,13,19,24; | [YA]WO2004026872 (SCHERING CORP [US]) [Y] 1,8,9,11,14-16,20,21,25,27,28 * page 24, line 29 - page 26, line 7 * [A] 2,13,19,24; | [XAY]EP1481678 (EISAI CO LTD [JP]) [X] 9,14,25,27,28 * paragraphs [0002] - [0003] * * paragraphs [0033] - [0035]; examples 1-4; tables 1-4 * [A] 2,13,19,24 [Y] 1,8,9,11,14-16,20,21,25,27,28; | [A] - SHIMIZU K ET AL, "Cancer anti-angiogenic therapy", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP LNKD- DOI:10.1248/BPB.27.599, (20040501), vol. 27, no. 5, ISSN 0918-6158, pages 599 - 605, XP002483110 [A] 1,2,8,9,11,13-16,19-21,24,25,27,28 * abstract * * table 1 * DOI: http://dx.doi.org/10.1248/bpb.27.599 | [A] - FUKUOKA K ET AL, "Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US LNKD- DOI:10.1023/A:1010608317361, (20010101), vol. 19, no. 3, ISSN 0167-6997, pages 219 - 227, XP002483112 [A] 1,2,8,9,11,13-16,19-21,24,25,27,28 * abstract * * figure 1 * DOI: http://dx.doi.org/10.1023/A:1010608317361 |